Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for CPP-115

Catalyst Pharmaceutical Partners, Inc.

today announced that the European Commission has granted orphan medicinal product designation for the company's investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, for the treatment of West Syndrome (infantile spasms). The EC designation is based on the recommendation by the European Medicines Agency (

) Committee on Orphan Medicinal Products after their review of all relevant preclinical data for CPP-115, which showed that it may have a longer duration of action, improved benefits and fewer retinal side effects than the existing first-line treatment.